SS
TCRT icon

Steve Schonfeld’s Alaunos Therapeutics TCRT Stock Holding History

Steve Schonfeld’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-283
Closed -$73K – 2995
2022
Q3 		$73K Buy
+283
New +$82.2K ﹤0.01% 2599
2021
Q1 		– Sell
-95
Closed -$36K – 2115
2020
Q4 		$36K Sell
95
-336
-78% -$134K ﹤0.01% 1510
2020
Q3 		$163K Sell
431
-196
-31% -$86.6K ﹤0.01% 1230
2020
Q2 		$308K Buy
+627
New +$280K 0.01% 986
2017
Q1 		– Sell
-73
Closed -$58K – 729
2016
Q4 		$58K Buy
+73
New +$65.8K 0.01% 526

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $610M AUM 17.84% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $1.07B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Steve Schonfeld's TCRT Position: Q4 2022 in Review

Steve Schonfeld sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 283 shares — an estimated $73K sold.

Steve Schonfeld first reported a position in TCRT in Q4 2016 and held it in 5 quarters. The position peaked at $308K in Q2 2020. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Steve Schonfeld reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Steve Schonfeld sold 283 Alaunos Therapeutics shares in Q4 2022, an estimated $73K.
  • Steve Schonfeld first reported a position in Alaunos Therapeutics in Q4 2016 and held it in 5 quarters.
  • Steve Schonfeld's Alaunos Therapeutics position peaked at $308K in Q2 2020.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.